VivoSeq
Immunology

X-Linked Severe Combined Immunodeficiency

2

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

X-linked Severe Combined Immunodeficiency is an early-stage landscape with 2 programs across 1 company. The most active players are Akero Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Akero Therapeutics logo

Akero Therapeutics

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical2

Busulfan

Akero Therapeutics

Palifermin

Swedish Orphan Biovitrum

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Protein / enzyme150%

Modality classified for 67% of 3 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT01306019·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)